Foster City, CA, United States of America

Xuelei Yan

USPTO Granted Patents = 31 (Patent Applications = 13)

CIPO Patents = 5 (Patent Applications = 5)

EPO Patents = 12 (Patent Applications = 14)

Average Co-Inventor Count = 7.9

ph-index = 4

Forward Citations = 61(Granted Patents)

Location History:

Burlingame, CA (US) (2008 - 2010)
Foster City, CA (US) (2009 - 2024)

Company Filing History:

Arcus Biosciences, Inc.

patents

6 out of 18

Oric Pharmaceuticals, Inc.

patents

Years Active: 2008-2025

where 'Filed Patents' based on already Granted Patents

31 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12410170 - 2,3,5-trisubstituted pyrazolo[1,5-A]pyrimidine compounds (2025-09-09),

2. 12384773 - Thiazole compounds and methods of use thereof (2025-08-12),

3. 12103907 - Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha (2024-10-01),

4. 11931343 - CD73 inhibitors (2024-03-19),

5. 11787762 - Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha (2023-10-17),

6. 11407721 - CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer (2022-08-09),

7. 11407712 - Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2α (2022-08-09),

8. 11306107 - Compounds that inhibit MCL-1 protein (2022-04-19),

9. 11274105 - Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonists (2022-03-15),

10. 11208432 - Inhibitors of glucocorticoid receptor (2021-12-28),

11. 11124537 - Inhibitors of glucocorticoid receptor (2021-09-21),

12. 11110103 - Inhibitors of glucocorticoid receptor (2021-09-07),

13. 10836789 - Inhibitors of glucocorticoid receptor (2020-11-17),

14. 10723759 - Inhibitors of glucocorticoid receptor (2020-07-28),

15. 10472387 - Inhibitors of glucocorticoid receptor (2019-11-12),

Title: Xuelei Yan: Innovator in Medical Chemistry and Patents

Introduction

Xuelei Yan, based in Foster City, California, is a notable inventor in the field of medical chemistry, holding an impressive portfolio of 29 patents. His work primarily focuses on developing compounds that target specific biological processes to combat various diseases, particularly cancer and immune-related disorders.

Latest Patents

Among his latest innovations, Yan has developed compounds such as tetralin and tetrahydroquinoline, which act as inhibitors of HIF-2alpha. These compounds and their associated compositions are designed to treat a range of health conditions by intervening in the mechanisms mediated by HIF-2α. Additionally, Yan's work on CD73 inhibitors, which modulate the conversion of AMP to adenosine, contributes to the development of therapies for diseases influenced by ecto-5'-nucleotidase. His patents outline the synthesis methods for these compounds and their applications in clinical settings.

Career Highlights

Xuelei Yan has made significant contributions to the pharmaceutical industry through his work with renowned companies. He has held pivotal positions at Amgen Inc. and Oric Pharmaceuticals, Inc., where he applied his expertise in medicinal chemistry to advance therapeutic solutions.

Collaborations

Throughout his career, Yan has collaborated with esteemed colleagues, including Daqing Sun and Yosup Rew. These collaborations have further enhanced his research initiatives and innovations in drug development.

Conclusion

Xuelei Yan's continued dedication to research and innovation in medical chemistry underscores his importance as an inventor. His extensive portfolio of patents showcases his role in addressing critical health challenges, making significant strides in developing potential treatments for prevalent diseases.

This text is generated by artificial intelligence and may not be accurate.